Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesE. Gabriela Chiorean, Andrew L. Coveler|Drug Design Development and Therapy|2015Cited by 252
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Chiara Cremolini, Federico Sanchez et al.|The Lancet Oncology|2023Cited by 244
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Hagop Kantarjian, Peter F. Thall et al.|Haematologica|2015Cited by 121
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).Andrew L. Coveler, T.R. Jeffry Evans, Farasat Kazmi et al.|Journal of Clinical Oncology|2021Cited by 6
354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)Andrew L. Coveler, T. R. J. Evans, Aglaia Skolariki et al.|Annals of Oncology|2022Cited by 3